Table 4.

Individual study data, pooled dataset, and pooled analysis of survival data and association between MMR and BRAFMT status

BRAFMTBRAFWTdMMRpMMR
dMMRpMMRdMMRpMMRBRAFMTBRAFWTBRAFMTBRAFWT
CAIRO
Number of patients1213629112613291
 PFSmo. (95% CI)6.6 (4.6–12.6)4.1 (2.4–6.4)3.6 (2.0–16.4)7.1 (6.4–8.2)6.6 (4.6–12.6)3.6 (2.0–16.4)4.1 (2.4–6.4)7.1 (6.4–8.2)
HR (95% CI)2.38 (0.80–7.09)3.19 (0.96–10.63)0.34 (0.08–1.44)2.60 (1.21–5.55)
 OSmo. (95% CI)13.2 (10.1–28.6)8.3 (5.9–13.6)18.6 (12.4–53.5)18.2 (16.2–19.4)13.2 (10.1–28.6)18.6 (12.4–53.5)8.3 (5.9–13.6)18.2 (16.2–19.4)
HR (95% CI)2.14 (0.70–6.54)0.97 (0.25–3.57)1.63 (0.34–7.77)3.29 (1.53–7.04)
CAIRO2
Number of patients123317454121733454
 PFSmo. (95% CI)5.7 (4.4–8.5)7.5 (6.4–9.7)9.3 (7.2–14.8)10.7 (9.9–12.1)5.7 (4.4–8.5)9.3 (7.2–14.8)7.5 (6.4–9.7)10.7 (9.9–12.1)
HR (95% CI)0.54 (0.22–1.34)1.25 (0.62–2.49)2.65 (0.95–7.41)1.79 (1.09–2.93)
 OSmo. (95% CI)10.4 (7.8–17.2)14.1 (11.5–19.4)21.0 (15.2–36.4)22.4 (21.1–25.0)10.4 (7.8–17.2)21.0 (15.2–36.4)14.1 (11.5–19.4)22.4 (21.1–25.0)
HR (95% CI)0.61 (0.25–1.52)1.14 (0.54–2.40)2.94 (1.02–8.52)2.04 (1.21–3.44)
COIN
Number of patients20100451,29620451001,296
 PFSmo. (95% CI)5.9 (5.4–8.5)5.8 (5.6–6.2)5.6 (5.1–6.1)6.6 (6.3–7.0)5.9 (5.4–8.5)5.6 (5.1–6.1)5.8 (5.6–6.2)6.6 (6.3–7.0)
HR (95% CI)1.05 (0.53–2.11)1.72 (1.14–2.60)0.78 (0.37–1.66)1.42 (1.07–1.88)
 OSmo. (95% CI)10.5 (8.2–16.3)10.2 (8.9–11.8)10.8 (9.2–14.0)16.7 (15.6–17.5)10.5 (8.2–16.3)10.8 (9.2–14.0)10.2 (8.9–11.8)16.7 (15.6–17.5)
HR (95% CI)1.04 (0.52–2.10)1.85 (1.19–2.88)1.08 (0.50–2.34)2.07 (1.54–2.79)
FOCUS
Number of patients9513267293251672
 PFSmo. (95% CI)6.8 (4.9–12.0)8.3 (6.8–9.1)8.3 (6.8–9.6)8.0 (7.4–8.3)6.8 (4.9–12.0)8.3 (6.8–9.6)8.3 (6.8–9.1)8.0 (7.4–8.3)
HR (95% CI)0.75 (0.28–2.00)0.91 (0.56–1.49)1.37 (0.49–3.79)0.93 (0.63–1.39)
 OSmo. (95% CI)13.5 (9.8–28.7)12.2 (10.2–14.8)17.5 (14.0–24.0)15.6 (14.7–16.9)13.5 (9.8–28.7)17.5 (14.0–24.0)12.2 (10.2–14.8)15.6 (14.7–16.9)
HR (95% CI)1.21 (0.44–3.36)0.85 (0.50–1.44)1.51 (0.52–4.42)1.55 (1.03–2.33)
Pooled dataset
Number of patients531971002,713531001972,713
 PFSmo. (95% CI)6.1 (5.6–7.7)6.2 (6.0–6.9)6.3 (5.8–7.4)7.8 (7.4–8.1)6.1 (5.6–7.7)6.3 (5.8–7.4)6.2 (6.0–6.9)7.8 (7.4–8.1)
HR (95% CI)0.95 (0.62–1.46)1.32 (1.00–1.75)1.07 (0.67–1.70)1.34 (1.10–1.64)
 OSmo. (95% CI)11.7 (9.9–14.4)11.3 (10.3–12.5)15.0 (13.1–18.0)17.3 (16.7–18.1)11.7 (9.9–14.4)15.0 (13.1–18.0)11.3 (10.3–12.5)17.3 (16.7–18.1)
HR (95% CI)1.05 (0.68–1.63)1.22 (0.91–1.65)1.51 (0.93–2.46)1.94 (1.57–2.40)

NOTE: Statistically significant results are shown in bold.

Abbreviations: mo., median PFS or OS time in months; mt, mutant tumor; wt, wild-type tumor.